Tarsus Pharmaceuticals, Inc. (TARS) Stock
5 of the hedge funds AlphaScala tracks reported TARS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $89.82M. Company insiders reported 0 open-market buys and 14 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own TARS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.43M | $89.82M | +153% |
| D.E. Shaw David Shaw | 711K | $44.72M | -10% |
| Citadel Ken Griffin | 242K | $15.21M | +47% |
| Hussman Investment Trust John Hussman | 21K | $1.32M | +25% |
| Renaissance Technologies Jim Simons (founder) | 9K | $585.3K | -87% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Tarsus Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Link William J Phd | Director | SELL | 11.7K | $915K |
| Sep 15, 26 | Link William J Phd | Director | SELL | 759 | $60K |
| Sep 15, 26 | Link William J Phd | Director | SELL | 66 | $5K |
| Sep 4, 26 | Neervannan Seshadri | Chief Operating Officer | SELL | 4.6K | $388K |
| Sep 4, 26 | Azamian Bobak R. | President/CEO and Board Chair | SELL | 7.1K | $641K |
| Sep 4, 26 | Azamian Bobak R. | President/CEO and Board Chair | SELL | 2.9K | $265K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 5.4K | $458K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 5.4K | $485K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1.6K | $135K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1.6K | $143K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →TARS price chart
Powered by TradingViewWhat does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of ophthalmic conditions. The company’s primary focus is on innovative treatments that address significant unmet medical needs in eye care, particularly in diseases affecting the anterior segment of the eye. Central to its portfolio is a targeted, investigational compound aimed at treating Demodex blepharitis, a common eyelid condition. Tarsus leverages advanced diagnostic tools and delivery mechanisms to enhance the efficacy and safety of its therapeutic candidates. Positioned within the dynamic biopharmaceutical industry, Tarsus Pharmaceuticals supports healthcare innovation by bridging gaps in available ophthalmic therapies. By prioritizing both patient outcomes and physician needs, the company plays a crucial role in the medical field, pushing boundaries in drug development and offering potential transformative solutions for eye health. Headquartered in Irvine, California, Tarsus continues to collaborate with researchers and clinical experts to advance its robust pipeline, reinforcing its commitment to addressing diverse ophthalmological challenges worldwide.